S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
Critical asset just had biggest fall on record (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
66,000% upside on tiny biotech? (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
66,000% upside on tiny biotech? (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
Critical asset just had biggest fall on record (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
66,000% upside on tiny biotech? (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
66,000% upside on tiny biotech? (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
Critical asset just had biggest fall on record (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
66,000% upside on tiny biotech? (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
66,000% upside on tiny biotech? (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
Critical asset just had biggest fall on record (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
66,000% upside on tiny biotech? (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
66,000% upside on tiny biotech? (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard

LeMaitre Vascular (LMAT) Competitors

$60.68
-1.61 (-2.58%)
(As of 02/22/2024 ET)

LMAT vs. TNDM, ATRC, FNA, NVCR, TMCI, MDXG, SIBN, EMBC, AORT, and ATEC

Should you be buying LeMaitre Vascular stock or one of its competitors? The main competitors of LeMaitre Vascular include Tandem Diabetes Care (TNDM), AtriCure (ATRC), Paragon 28 (FNA), NovoCure (NVCR), Treace Medical Concepts (TMCI), MiMedx Group (MDXG), SI-BONE (SIBN), Embecta (EMBC), Artivion (AORT), and Alphatec (ATEC). These companies are all part of the "surgical & medical instruments" industry.

LeMaitre Vascular vs.

LeMaitre Vascular (NASDAQ:LMAT) and Tandem Diabetes Care (NASDAQ:TNDM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, community ranking, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

84.6% of LeMaitre Vascular shares are owned by institutional investors. 12.4% of LeMaitre Vascular shares are owned by company insiders. Comparatively, 2.5% of Tandem Diabetes Care shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

LeMaitre Vascular currently has a consensus price target of $67.60, suggesting a potential upside of 11.40%. Tandem Diabetes Care has a consensus price target of $36.23, suggesting a potential upside of 44.92%. Given Tandem Diabetes Care's higher possible upside, analysts clearly believe Tandem Diabetes Care is more favorable than LeMaitre Vascular.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LeMaitre Vascular
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.57
Tandem Diabetes Care
1 Sell rating(s)
8 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.23

In the previous week, Tandem Diabetes Care had 8 more articles in the media than LeMaitre Vascular. MarketBeat recorded 14 mentions for Tandem Diabetes Care and 6 mentions for LeMaitre Vascular. LeMaitre Vascular's average media sentiment score of 0.55 beat Tandem Diabetes Care's score of 0.51 indicating that LeMaitre Vascular is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
LeMaitre Vascular
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Tandem Diabetes Care
9 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

LeMaitre Vascular has a net margin of 14.69% compared to Tandem Diabetes Care's net margin of -27.02%. LeMaitre Vascular's return on equity of 9.83% beat Tandem Diabetes Care's return on equity.

Company Net Margins Return on Equity Return on Assets
LeMaitre Vascular14.69% 9.83% 8.52%
Tandem Diabetes Care -27.02%-23.90%-8.73%

LeMaitre Vascular has higher earnings, but lower revenue than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LeMaitre Vascular$161.65M8.36$20.64M$1.2150.15
Tandem Diabetes Care$801.22M2.03-$94.59M-$3.23-7.74

Tandem Diabetes Care received 68 more outperform votes than LeMaitre Vascular when rated by MarketBeat users. However, 70.94% of users gave LeMaitre Vascular an outperform vote while only 61.24% of users gave Tandem Diabetes Care an outperform vote.

CompanyUnderperformOutperform
LeMaitre VascularOutperform Votes
493
70.94%
Underperform Votes
202
29.06%
Tandem Diabetes CareOutperform Votes
561
61.24%
Underperform Votes
355
38.76%

LeMaitre Vascular has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Comparatively, Tandem Diabetes Care has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500.

Summary

LeMaitre Vascular beats Tandem Diabetes Care on 12 of the 17 factors compared between the two stocks.


Get LeMaitre Vascular News Delivered to You Automatically

Sign up to receive the latest news and ratings for LMAT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LMAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LMAT vs. The Competition

MetricLeMaitre VascularSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$1.35B$3.91B$5.15B$7.53B
Dividend Yield0.90%2.05%2.91%3.86%
P/E Ratio50.1523.10127.7918.29
Price / Sales8.3624.563,006.4081.55
Price / Cash41.7331.2189.9753.30
Price / Book4.984.034.304.60
Net Income$20.64M$20.55M$112.86M$207.29M
7 Day Performance-2.99%-1.22%0.45%-1.02%
1 Month Performance3.58%9.73%6.45%3.31%
1 Year Performance23.38%3.10%8.11%3.73%

LeMaitre Vascular Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TNDM
Tandem Diabetes Care
3.9364 of 5 stars
$23.56
-3.5%
$37.36
+58.6%
-37.6%$1.54B$771.42M-7.292,600Options Volume
News Coverage
Gap Up
ATRC
AtriCure
2.0656 of 5 stars
$33.01
+0.9%
$57.88
+75.3%
-20.0%$1.56B$399.24M-50.021,050
FNA
Paragon 28
2.3649 of 5 stars
$13.73
-1.5%
$22.33
+62.7%
-26.0%$1.14B$181.38M-16.15463Upcoming Earnings
News Coverage
NVCR
NovoCure
4.0165 of 5 stars
$15.82
-2.0%
$41.71
+163.7%
-81.4%$1.69B$537.84M-8.511,320Analyst Report
News Coverage
TMCI
Treace Medical Concepts
2.8278 of 5 stars
$15.29
-1.5%
$19.58
+28.1%
-35.6%$943.09M$141.84M-19.35423Upcoming Earnings
MDXG
MiMedx Group
2.4176 of 5 stars
$8.04
-0.2%
$11.67
+45.1%
+80.2%$935.70M$267.84M-402.00867Upcoming Earnings
Insider Selling
News Coverage
SIBN
SI-BONE
3.7946 of 5 stars
$20.80
-0.6%
$26.33
+26.6%
+17.6%$842.40M$106.41M-17.48357Upcoming Earnings
EMBC
Embecta
3.067 of 5 stars
$14.30
-1.2%
$16.00
+11.9%
-53.2%$823.38M$1.12B15.052,200Positive News
AORT
Artivion
2.4516 of 5 stars
$18.70
-0.6%
$23.50
+25.7%
+46.7%$766.70M$354M-24.931,300Insider Selling
High Trading Volume
ATEC
Alphatec
4.1524 of 5 stars
$15.40
-0.8%
$22.63
+46.9%
+7.3%$2.10B$350.87M-10.20705Upcoming Earnings
Insider Selling

Related Companies and Tools

This page (NASDAQ:LMAT) was last updated on 2/23/2024 by MarketBeat.com Staff